A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer
- 31 December 1994
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 30 (2) , 188-194
- https://doi.org/10.1016/0959-8049(94)90085-x
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Chemotherapy of Lung CancerNew England Journal of Medicine, 1992
- Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer.Journal of Clinical Oncology, 1990
- New drugs in the management of small cell lung cancerLung Cancer, 1989
- Intensive chemotherapy of small cell lung cancerLung Cancer, 1989
- Unexpected high toxicity in a phase II study of teniposide (VM-26) in elderly patients with untreated small cell lung cancer (SCLC)European Journal of Cancer and Clinical Oncology, 1988
- Structure-bioactivation relationship of a series of podophyllotoxin derivativesEuropean Journal of Cancer and Clinical Oncology, 1988
- New drugs in small-cell lung cancerCancer Treatment Reviews, 1986
- A Case of Small Cell Lung Cancer Successfully Treated with VM26Japanese Journal of Clinical Oncology, 1986
- Establishment of an etoposide‐resistant human epithelial tumour cell line In vitro: Characterization of patterns of cross‐resistance and drug sensitivitiesInternational Journal of Cancer, 1984
- VM26 (NSC-122819): A clinical study in advanced cancer of the lung and ovaryPublished by Elsevier ,1978